Pyridostatin Trifluoroacetate(RR82)

Molecular Weight (MW)	938.72
Formula	C37H35F9N8O11
CAS No.	1472611-44-1 TFA salt
Storage	-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)	DMSO: 100 mg/mL
Water: 100 mg/mL
Ethanol: 30 mg/mL
Other info	Chemical Name: 4-(2-aminoethoxy)-N2,N6-bis(4-(2-aminoethoxy)quinolin-2-yl)pyridine-2,6-dicarboxamide tris(2,2,2-trifluoroacetate) InChi Key: CYYZQGUDHAKBIQ-UHFFFAOYSA-N InChi Code: InChI=1S/C31H32N8O5.3C2HF3O2/c32-9-12-42-19-15-24(30(40)38-28-17-26(43-13-10-33)20-5-1-3-7-22(20)36-28)35-25(16-19)31(41)39-29-18-27(44-14-11-34)21-6-2-4-8-23(21)37-29;33-2(4,5)1(6)7/h1-8,15-18H,9-14,32-34H2,(H,36,38,40)(H,37,39,41);3(H,6,7) SMILES Code: O=C(C1=NC(C(NC2=NC3=CC=CC=C3C(OCCN)=C2)=O)=CC(OCCN)=C1)NC4=NC5=CC=CC=C5C(OCCN)=C4.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
Synonyms	RR-82; PDS; RR 82; RR82; Pyridostatin TFA salt

Molecular Weight (MW)

938.72

Formula

C37H35F9N8O11

CAS No.

1472611-44-1 TFA salt

Storage

-20℃ for 3 years in powder form

-80℃ for 2 years in solvent

Solubility (In vitro)

DMSO: 100 mg/mL

Water: 100 mg/mL

Ethanol: 30 mg/mL

Other info

Chemical Name: 4-(2-aminoethoxy)-N2,N6-bis(4-(2-aminoethoxy)quinolin-2-yl)pyridine-2,6-dicarboxamide tris(2,2,2-trifluoroacetate)

InChi Key: CYYZQGUDHAKBIQ-UHFFFAOYSA-N

InChi Code: InChI=1S/C31H32N8O5.3C2HF3O2/c32-9-12-42-19-15-24(30(40)38-28-17-26(43-13-10-33)20-5-1-3-7-22(20)36-28)35-25(16-19)31(41)39-29-18-27(44-14-11-34)21-6-2-4-8-23(21)37-29;3*3-2(4,5)1(6)7/h1-8,15-18H,9-14,32-34H2,(H,36,38,40)(H,37,39,41);3*(H,6,7)

SMILES Code: O=C(C1=NC(C(NC2=NC3=CC=CC=C3C(OCCN)=C2)=O)=CC(OCCN)=C1)NC4=NC5=CC=CC=C5C(OCCN)=C4.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F

Synonyms

RR-82; PDS; RR 82; RR82; Pyridostatin TFA salt

In Vitro	In vitro activity: Pyridostatin decreases the proliferation of MRC-5–SV40 cells and various cancer cell lines, and induces cell-cycle arrest by DNA-damage checkpoint activation. Pyridostatin also reduces SRC-dependent cell motility in MDA-MB-231 cells by interacting with G-quadruplex motifs in SRC. Pyridostatin decreases EBNA1 synthesis via inhibition of G-quadruplexes. Cell Assay: Cells (MRC-5–SV40 cells and various cancer cell lines) are plated at equal confluence and are left either untreated or were treated with 2 μM pyridostatin continually during the indicated time before harvesting the cells. Cells from individual plates are trypsinized and counted in a Coulter counter. Graphs represent the total cell numbers at each time interval, and the error bars represent the s.e.m. Data represent three independent experiments.
In Vivo
Animal model
Formulation & Dosage
References	Nat Chem Biol. 2012 Feb 5;8(3):301-10; Nat Chem Biol. 2014 May;10(5):358-64.

In Vitro

In vitro activity: Pyridostatin decreases the proliferation of MRC-5–SV40 cells and various cancer cell lines, and induces cell-cycle arrest by DNA-damage checkpoint activation. Pyridostatin also reduces SRC-dependent cell motility in MDA-MB-231 cells by interacting with G-quadruplex motifs in SRC. Pyridostatin decreases EBNA1 synthesis via inhibition of G-quadruplexes.

Cell Assay: Cells (MRC-5–SV40 cells and various cancer cell lines) are plated at equal confluence and are left either untreated or were treated with 2 μM pyridostatin continually during the indicated time before harvesting the cells. Cells from individual plates are trypsinized and counted in a Coulter counter. Graphs represent the total cell numbers at each time interval, and the error bars represent the s.e.m. Data represent three independent experiments.

In Vivo

Animal model

Formulation & Dosage

References

Nat Chem Biol. 2012 Feb 5;8(3):301-10; Nat Chem Biol. 2014 May;10(5):358-64.

CAS NO:	1472611-44-1
规格:	≥98%

包装	价格(元)
5mg	电议
10mg	电议
25mg	电议
50mg	电议
100mg	电议
250mg	电议
500mg	电议